title: Making a case for acute ischemic stroke.
abstract: Stroke is the third leading cause of death in the United States and the number one cause of adult long-term disability. Disability in stroke survivors includes hemiparesis, aphasia, inability to walk without assistance, dependence on others for activities of daily living, depression, and institutionalization. Immediate recognition of acute ischemic stroke (AIS) signs and symptoms is required because many treatment options are time sensitive. Hospital transport via activation of 911 and emergency medical services (EMSs) removes delays to urgent diagnosis and intervention. Intravenous (IV) recombinant tissue plasminogen (rt-PA) is a time-sensitive reperfusion strategy. The American Heart Association (AHA) and American Stroke Association (ASA) recently revised recommendations that the time window for IV rt-PA be expanded from 3 hours to 4.5 hours after symptom onset in patients with mild to moderate stroke. Supportive therapies include crystalloid IV solutions, adequate oxygenation, and normothermia. Best rest is desired along with oxygen supplementation. Avoidance of fever is paramount since fever can contribute to negative outcomes. It is the purpose of this article to review risk factors, stroke symptoms, epidemiology, and current drug therapy of AIS. Standards of care will be reviewed.
authors.affiliation: Department of Neurology, Baptist Medical Center, Jacksonville, FL 32207, USA. Kathleen.baldwin@bmcjax.com
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Baldwin
authors.forename: Stacey L
authors.initials: SL
authors.lastname: McCoy
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D004632:Emergency Medical Services / Q000379:methods; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology / Q000628:therapy; D059039:Standard of Care; D020521:Stroke / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator